GALAPAGOS NV/S (NASDAQ:GLPG) Downgraded to “Sell” at BidaskClub

GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Thursday, April 18th, BidAskClub reports.

Several other brokerages have also commented on GLPG. ValuEngine raised shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 4th. HC Wainwright boosted their price target on shares of GALAPAGOS NV/S to $150.00 and gave the company a “positive” rating in a research report on Friday, March 29th. Zacks Investment Research lowered shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Svb Leerink began coverage on shares of GALAPAGOS NV/S in a research report on Friday, February 22nd. They issued an “outperform” rating on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, February 22nd. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $127.27.

GALAPAGOS NV/S stock traded up $1.33 during midday trading on Thursday, hitting $116.78. 163,070 shares of the stock were exchanged, compared to its average volume of 109,039. The stock has a market cap of $5.92 billion, a PE ratio of -176.94 and a beta of 1.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.31. GALAPAGOS NV/S has a 52-week low of $85.00 and a 52-week high of $125.48.

Hedge funds have recently added to or reduced their stakes in the business. We Are One Seven LLC purchased a new position in GALAPAGOS NV/S in the 4th quarter worth approximately $27,000. Wells Fargo & Company MN boosted its stake in shares of GALAPAGOS NV/S by 66.3% in the 1st quarter. Wells Fargo & Company MN now owns 1,678 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 669 shares in the last quarter. Pinnacle Associates Ltd. bought a new stake in GALAPAGOS NV/S during the 1st quarter valued at $231,000. Financial Gravity Companies Inc. bought a new stake in GALAPAGOS NV/S during the 4th quarter valued at $233,000. Finally, Townsquare Capital LLC bought a new stake in GALAPAGOS NV/S during the 4th quarter valued at $279,000. 15.87% of the stock is owned by institutional investors and hedge funds.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Total Return

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.